Phase 3 trial of Descartes-08 in myasthenia gravis to start in 1H25
Cartesian Therapeutics has secured an agreement from the US Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for its phase 3 AURORA trial of Descartes-08, an mRNA cell therapy candidate for myasthenia gravis (MG).
This approval means the FDA has deemed the trial design acceptable to support a future Biologics License Application for Descartes-08 in MG, contingent on trial outcomes.
“This SPA agreement marks an important milestone,” said Carsten Brunn, PhD, President and CEO of Cartesian: “It provides critical regulatory clarity and a clear path toward potential approval.”
The phase 3 AURORA trial will assess Descartes-08 versus placebo with a 1:1 randomisation. The treatment involves six once-weekly infusions without preconditioning chemotherapy in 100 participants with acetylcholine receptor autoantibody positive MG.
The primary endpoint is the proportion of Descartes-08 participants showing a three-point or more improvement in MG-ADL score at month 4 compared to placebo.
In December 2024, Cartesian announced positive results from the phase 2b trial, demonstrating deep and durable improvements in MG patients.
Dr Brunn noted: “Supported by compelling phase 2b results, we believe Descartes-08 has the potential to serve as a meaningful new therapy without the need for preconditioning chemotherapy.”
Myasthenia gravis is a chronic autoimmune disorder that causes muscle weakness and fatigue, often requiring chronic immunosuppressive medicines.
Descartes-08 is designed to target B-cell maturation antigen and is in clinical development for MG and systemic lupus erythematosus. Dr Brunn added: “We look forward to commencing the phase 3 AURORA trial in the first half of this year.”

Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

AAV Packaging Services
READ MORE

Off-the-Shelf AAV Products
READ MORE